Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

European Journal of Endocrinology, Vol 135, Issue 2, 216-221
Copyright © 1996 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colombo, P
Right arrow Articles by Fazio, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colombo, P
Right arrow Articles by Fazio, F
Articles

Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region

P Colombo, AG Siccardi, G Paganelli, P Magnani, C Songini, R Buffa, G Faglia, and F Fazio

Institute of Endocrine Sciences, Ospedale Maggiore IRCCS, Milan, Italy.

In the present paper we evaluated the ability of pretargeted immunoscintigraphy (ISG) with antichromogranin A (CgA) monoclonal antibody (Mc-ab A11) in visualizing pituitary masses. The results obtained in 23 patients are described along with those of [111In]pentetreotide scintigraphy (Octreoscan) in 18 cases. Positive ISG was obtained in 9/11 (82%) non-functioning, 1/4 growth hormone-, 1/2 prolactin-, 1/2 thyrotropin-, 1/1 follicle-stimulating hormone-, 0/1 adrenocortico-trophin-secreting pituitary adenomas. In one patient with a positive ISG scan of a non-functioning pituitary adenoma, an associated neurinoma of the acoustic nerve was not imaged. The same occurred in one patient with a pituitary deposit from a mammary carcinoma and in another one with a cyst of the Rathke's pouch. Chromogranin A immunohistochemistry, carried out in 10 tumours, was positive in eight pituitary adenomas and negative in two non-adenomatous lesions. A concordant ISG occurred in all cases except for two pituitary adenomas: one cystic and necrotized and one post-operative remnant very small in size. In 18 patients with pituitary adenoma both ISG and Octreoscan were positive in 61% of cases but with a different distribution among tumours. At variance with ISG, Octreoscan visualized only 5/10 (50%) non-functioning pituitary adenomas and all (4/4) somatotropinomas. In conclusion, ISG is able to image pituitary tumours and particularly non-functioning pituitary adenomas. In this respect, it may be helpful in discriminating non-neuroendocrine masses of the pituitary region from non-functioning pituitary adenomas.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Zatelli, D. Piccin, A. Bottoni, M. R. Ambrosio, A. Margutti, R. Padovani, M. Scanarini, J. E. Taylor, M. D. Culler, L. Cavazzini, et al.
Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on {alpha}-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomas in Vitro
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5181 - 5188.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Barzon, M. Boscaro, and G. Palu
Endocrine Aspects of Cancer Gene Therapy
Endocr. Rev., February 1, 2004; 25(1): 1 - 44.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. C. Boerman, F. G. van Schaijk, W. J.G. Oyen, and F. H.M. Corstens
Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
J. Nucl. Med., March 1, 2003; 44(3): 400 - 411.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 European Society of Endocrinology.